Companies › Veradermics
1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 2; Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VDPHL01 Androgen pathway modulator for androgenetic alopecia | – | Phase 3 | Androgenetic Alopecia; Androgenetic Alopecia (AGA) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06724614 | VDPHL01 | Phase 2 | Androgenetic Alopecia | Immunology | Feb 2026 |
| NCT06527365 | VDPHL01 | Phase 2 | Androgenetic Alopecia | Immunology | Aug 2026 |
| NCT06972264 | VDPHL01 | Phase 3 | Androgenetic Alopecia | Immunology | Dec 2026 |
| NCT07146022 | VDPHL01 | Phase 3 | Androgenetic Alopecia (AGA) | Immunology | Jun 2027 |
Cash and short-term investments of $820m on 2026-06-30; operating cash outflow about $72m a year; runway about 136 months at that burn, to Oct 2037; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Palisade Bio Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals Fujian Mindong Rejuvenation Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.